Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T5OX
|
|||
| Former ID |
DAP000264
|
|||
| Drug Name |
Remifentanil
|
|||
| Synonyms |
Remifentanyl; Ultiva; GI 87084B; GI 87084X; GI87084B; Remifentanil (INN); Remifentanil [INN:BAN]; Ultiva (TN); Methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate; 1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester; 3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester; 4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anaesthesia [ICD-11: 9A78.6; ICD-9: 338] | Approved | [1], [2] | |
| Therapeutic Class |
Hypnotics and Sedatives
|
|||
| Company |
Abbott Laboratories
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H28N2O5
|
|||
| Canonical SMILES |
CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC
|
|||
| InChI |
1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
|
|||
| InChIKey |
ZTVQQQVZCWLTDF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 132875-61-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10221, 6595876, 7980495, 8187072, 14902224, 43118154, 46504538, 50016966, 57314129, 76410936, 85209930, 93166187, 96025159, 103267286, 104321713, 117552936, 124403616, 129954253, 134224470, 134337578, 135049469, 137003165, 139212458, 160964238, 164814940, 175267741, 178103866, 179149818, 226422640, 250135003
|
|||
| ChEBI ID |
CHEBI:8802
|
|||
| ADReCS Drug ID | BADD_D01923 ; BADD_D02430 | |||
| SuperDrug ATC ID |
N01AH06
|
|||
| SuperDrug CAS ID |
cas=132875617
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Agonist | [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7292). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020630. | |||
| REF 3 | The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.